How Do Clinics Calculate the ROI of a Prior Authorization Model?

What Is a Prior Authorization ROI Model?

A prior authorization ROI model estimates the financial return created by improving how a clinic obtains, tracks, and follows up on insurer approval for medically necessary services, drugs, tests, or equipment. It is not simply a calculation of money saved by preventing denials. A credible model also measures staff time, patient delay, rework, leakage, denial risk, and the value of approved care reaching the patient. For care networks, these variables can be observed across thousands of authorization requests, but a clinic with only a few hundred monthly cases may need to rely on a smaller, operationally focused sample.

Also worth reading: How Do Prior Authorization Analytics Improve Care Coordination Without Adding More Administrative Work? · What Are the Best Benchmarks for Measuring Prior Authorization Denial Performance in 2026? · What Should a Prior Authorization Dashboard Actually Measure in 2026?

The basic return calculation compares the annualized benefit of the program with its total annualized cost. If a clinic spends $120,000 per year on authorization software, implementation, training, and staff time while recovering $180,000 in avoided denials, faster reimbursement, and reduced rework, its first-year ROI is 50%. That result does not mean every dollar of software cost produced a direct denial recovery. It means the combined, measurable benefits exceeded the stated investment by $60,000 before considering taxes or other accounting adjustments.

A useful distinction is between authorization ROI and broader revenue-cycle ROI. Authorization systems may influence clean-claim rates and days in outstanding receivables, but those effects should be isolated or estimated separately rather than counted twice. Similarly, faster approval can create clinical value by reducing treatment delays, yet that patient benefit should not be assigned an invented dollar amount unless the clinic has a defensible method for doing so. The strongest model therefore separates hard financial value from clinical and experience measures.

For B2B care-coordination and patient-pulse platforms, the objective is usually not to approve every request automatically. It is to give clinicians and coordinators reliable visibility, collect complete clinical evidence, surface status changes, route exceptions, and make delays visible before they become abandoned care. That operational role matters because a nominally high-value software product with incomplete payer data or burdensome workflows may generate a negative return.

How the ROI Calculation Works

A practical model begins with authorization volume. Suppose a clinic network handles 8,000 authorization requests per year and currently employs 3.0 full-time-equivalent staff members devoted partly to status checks, documentation requests, calls, and appeals. If a platform saves an average of eight minutes per case, the gross capacity recovered is 1,066.7 hours per year, equivalent to roughly 0.51 FTE at 2,080 productive hours. At a fully loaded labor cost of $65 per hour, the gross staffing-capacity value is about $69,333, but this is not automatically cash savings unless staffing, overtime, or contractor expense actually changes.

The next component is avoided rework. A manager should classify each request as first-pass accepted, rejected for missing information, administratively denied, clinically denied, or approved after escalation. The program target might be to reduce first-pass rejection from 12% to 7%. Applied to 8,000 requests, that is 400 fewer administrative rework events, not 400 guaranteed claim denials. If each event consumes 35 minutes, the organization recovers 233 hours. Multiplying by a validated internal cost rate gives a benefit estimate, while avoiding arbitrary savings claims when a team has enough spare capacity to absorb the work without reducing labor expense.

A second core formula is days in authorization and payment status. If median approval time falls from 12 days to 6 days for 1,600 payable authorizations, the network has 9,600 authorization-days removed, or 26.3 FTE-days of work visibility. Financial value should be tied to actual working-capital effects rather than the gross value of all accelerated claims. For example, a clinic may use 7 days to submit the clean claim and may not bill the payer until an approval number is available, so six faster days can materially shorten days in receivables. A precise model should verify those workflow rules by service line and payer.

The final layer is avoided leakage. If historical data shows that 4% of required approvals are never resubmitted after a denial, each recovered case should be valued according to its expected collectible revenue and contribution margin—not its full charge. The model should not count expected gross charges as savings because some approved services later become uncollectible or unnecessary. It should also exclude cases that would have been approved without platform involvement, because attributing every post-launch payment to the new system overstates return.

## Building a Baseline Before Purchasing Technology

The most credible ROI model starts before implementation. Clinics should collect at least 12 months of baseline data where available, while recognizing that staffing levels, payer mix, service volume, and policy changes can make a three-year average more useful than a single month. Useful fields include request date, payer, service, urgency, first submission date, information request date, approval date, denial date, final disposition, appeal outcome, amount billed, amount collected, and staff minutes. The data should distinguish required prior authorization from retrospective review because expected value differs sharply between them.

A workable pilot can be narrower. A specialty clinic might select 600 high-volume prior authorization requests over eight weeks and compare them with a matched historical period. If first-pass rejection is initially 14% and falls to 8%, the absolute improvement is six percentage points. On 600 cases, that is 36 fewer rejected submissions. Whether that produces 36 additional approvals depends on clinical eligibility, payer behavior, and appeal success, so the model should measure each step in the funnel rather than assume a 100% conversion.

The organization should establish a target population and prevent selection bias. Comparing the easiest drug requests in one clinic with complex infusion requests in another would create an attractive but unreliable result. A stronger pilot preserves service-line and payer mix, uses comparable months, and accounts for policy updates. If a major insurer changed its portal or form in March 2026, a January-versus-April comparison may reflect that external event rather than the new workflow.

Sensitivity analysis is equally important. Management can model low, base, and high cases for labor value, approval rate, recovered revenue, and implementation cost. In the base case, a system may save 900 hours and recover 200 previously abandoned cases, but only 100 of those cases may be collectible. The low case uses 500 hours, 100 recovered cases, and no staffing reduction, while the high case assumes 1,300 hours, 300 recovered cases, and 0.5 FTE avoided. The range communicates uncertainty better than one deterministic percentage and helps procurement teams identify which assumption creates most of the claimed return.

The baseline should also include a “do nothing” cost. A clinic may already employ staff who check status manually, so software that merely makes them click the same buttons more quickly is unlikely to justify a large subscription. Conversely, a clinic with fragmented fax, portal, email, and voicemail workflows may have a strong operational case. The correct comparison is often not software versus no software, but software versus the current process and its measurable risk.

Direct-to-Patient Pricing and Other Value Considerations

Direct-to-patient drug pricing can complicate a prior authorization ROI model because patients may ask why an approved amount differs from a cash price shown online or at a pharmacy. This does not make cash pricing the correct alternative for every case. A self-pay purchase can be faster, but it may not be clinically appropriate, may fall outside the prescriber’s treatment decision, and can shift substantial cost to the patient. The model should compare only clinically equivalent, actually available options and should include affordability, adherence, and downstream treatment effects.

For a high-cost specialty drug, for example, an authorization program might prevent a $2,000 administration fee from becoming unnecessary when coverage is denied. If a cash price is $1,600 and the anticipated insurer-covered cost to the clinic is $400 after patient assistance, the economic choices cannot be compared by sticker price alone. One option may preserve predictable collection and patient support, while another may reduce immediate outlay but increase abandonment risk. A clinic should not present a direct cash transaction as pure savings unless the prescriber confirms equivalence and the patient can responsibly obtain and use the medicine.

Prior authorization ROI also overlaps with patient-pulse communication. When patients receive a clear notice that approval is pending, a required document is missing, or an appeal has begun, they may make fewer duplicate calls and provide documents sooner. Those effects should be measured with call volume, median response time, and abandonment before assigning value. A reduction from 500 authorization-related calls per month to 400 is a 20% decrease and 100 calls; at 6 minutes per call, it releases 10 hours. It becomes cash savings only if those calls previously drove paid contractor work, overtime, or measurable new staffing.

Patient outcomes belong in the model but need careful treatment. Shorter approval times may help a patient start therapy earlier, but software cannot guarantee adherence, clinical response, or avoidance of hospitalization. The organization can report the number of delayed starts reduced, time to treatment where data are reliable, and patient-reported clarity. Converting those outcomes into dollars can be appropriate when supported by peer-reviewed evidence or local outcomes, but an unsupported multiplier makes the business case look stronger than the evidence permits.

The date context also matters. A 2026 evaluation should review current payer rules, state requirements, vendor contracts, and recent CMS policy developments rather than relying on a generic prior authorization article. The public discussion around WISeR and AI-assisted claims review shows that automation creates policy questions as well as efficiency questions. A clinic should prefer explainable rules, human review of adverse or ambiguous decisions, audit logs, and documented override paths. An AI feature that saves time but creates unmanageable appeals or equity concerns is not a positive long-term return.

Implementation Costs and Pricing Logic

There is no responsible universal market price for a prior authorization ROI model or its supporting platform. Pricing may be per provider, per facility, per authorization, per service line, or an enterprise subscription, and clinics should compare the unit that matches actual workload. A vendor that prices per facility may be economical for a large network, while a small clinic handling 150 requests per month could prefer a per-request arrangement. Artificial transaction thresholds and platform fees can materially change a three-year total cost of ownership.

The model should include more than the annual license. Costs can include implementation, data migration, payer-rule configuration, interface work, security review, training, help-desk support, change management, and the staff time required to operate exceptions. If a network pays $75,000 in year one for software and $60,000 annually thereafter, while first-year implementation and internal effort add $85,000, the first-year cost is $160,000 before benefits. A three-year comparison would then require explicit assumptions about escalation, renewal increases, and staffing benefits rather than simply multiplying the subscription price by three.

The payback period is the time required for cumulative measurable benefits to recover the investment. If cumulative first-year cost is $160,000 and monthly net benefit starts at $10,000 and rises to $15,000 after month four, the system crosses the investment during month 12 or 13 depending on the exact ramp. This is more informative than ROI alone for cash planning. A high-return project with a 30-month payback may be less suitable for a constrained clinic than a lower-return project that breaks even in eight months.

Procurement teams should request transparent pricing and ask whether the quoted result includes fax handling, portal connections, status checks, clinical documentation retrieval, appeals, patient notifications, and reporting. Low headline prices may exclude exactly the high-touch workflows that create value. Conversely, a high price may still be justified if it replaces several vendors, reduces denied days at scale, and can be deployed without extensive custom work. A 24-month pilot with clear termination terms can protect the clinic, but vendor lock-in and unrecoverable configuration work should be considered.

Quantifiable return should be validated against net benefit, not software-created activity. If the platform generates 5,000 status checks, the fact that automation performed them does not mean the clinic saved the equivalent of five full-time positions. Some checks are necessary, and humans may simply move to unresolved exceptions. A credible case uses before-and-after outcomes, then asks whether the clinic changed staffing, contractor use, collection performance, leakage, or patient communication as a result.

Common Mistakes That Inflate the ROI

The most frequent error is treating the full billed value of reauthorized care as recovered cash. A $50,000 infusion may have a $10,000 expected contribution margin, while a $5,000 imaging study may have a much different margin. ROI should use collected revenue or contribution margin supported by historical payment rates, with write-offs and patient responsibility included. Another mistake is assuming every prior authorization denial is avoidable. Some requests are correctly denied because the payer’s medical policy does not support the requested service, and appealing those cases may consume more than they recover.

A second error is comparing an authorization approval with a clean claim. Approval does not ensure that documentation, coding, coverage, and claim submission requirements are all satisfied. The model should connect authorization metrics to clean-claim submission and collection, but not claim that a lower denial rate automatically equals a higher net collection rate. Payer estimates can also differ from final adjudication, so recovered amounts should be based on posted payments or conservative expected values.

The third mistake is double counting faster payment. A model may count days-sales-outstanding improvement as a benefit and then count the same accelerated cash again as revenue leakage recovery. Benefits should be divided into mutually exclusive categories: incremental collection, avoided rework, changed labor cost, lower appeal expense, and separately reported clinical or patient value. If the organization uses a working-capital factor to value faster cash, it should not also book the full receivable as income.

The fourth mistake is ignoring implementation disruption. During onboarding, teams may enter historical data, retrain staff, and handle parallel manual processes. Launch-period costs and temporary productivity loss should be included. Vendors may also promise high automation based on a narrow test set, while real networks contain multiple payers, older systems, unusual requests, and low-quality clinical documentation. An exception rate above expectations does not mean the project failed automatically, but it changes the staffing and benefit assumptions.

The fifth mistake is omitting patient harm and equity. If faster processing is achieved only for commercially attractive cases while complex patients face more delay, the apparent ROI may hide a poor care outcome. Clinics should review approval times by language, insurance type, service, and relevant demographic groups, subject to privacy and data-quality limits. Human review remains important when a software recommendation affects clinical evidence, an urgent request, or a vulnerable population. A defensible model values consistency, not just the average number of cases processed per day.

How to Compare Alternatives and Decide When to Act

A clinic can compare four alternatives: no new system, a portal-and-spreadsheet process, a modular authorization service, and an integrated care-coordination platform. The current manual process may still be best when volume is low and staff can manage it reliably. For example, 50 simple requests per month with short processing times may not justify a large enterprise contract. A spreadsheet may be adequate for a small pilot, but it often lacks audit trails, escalation reminders, payer-specific logic, and real-time status visibility.

Modular tools may offer lower upfront cost and stronger functionality in one area, such as e-fax intake or status checks. An integrated platform may cost more but connect authorization data with patient communications, scheduling, utilization review, and care-team work queues. The best choice depends on workflow fit. If clinicians must copy information among three systems, integration may be worth more than additional automation inside one narrow portal.

The clinic should act when a measurable problem is persistent, not merely because prior authorization is a popular software category. Warning signs include a first-pass rejection rate above 10%, more than 5% of pending requests aging beyond 30 days, repeated manual status checks, or abandonment of otherwise billable services. These are not universal compliance benchmarks; they are operating triggers that should be adjusted for complexity. A specialist oncology infusion center may tolerate a different process from a primary-care clinic because payer evidence, treatment urgency, and service economics differ.

A decision gate can require four conditions: at least 80% of relevant request volume is included in measurement; the pilot has a documented comparison group or matched baseline; benefits are verified from financial or operational records; and the organization can explain how staff will handle exceptions. The business case should then be rerun after 90 days and again after six to twelve months. If the system reduces status labor but does not improve collection or leakage, the buyer should reconsider its price or use case rather than protect the original forecast.

What a Defensible Board-Level ROI Report Should Contain

A board-level report should show the calculation, the assumptions, and the limits in the same section. It should state the measurement period, number of requests, payer mix, service lines, cost definition, labor rate, recovery rate, and whether results were directly observed or modeled. A one-page dashboard can present ROI, payback, first-pass rejection, median approval time, requests over 14 days, abandonment recovery, and patient communication metrics, while an appendix holds the formulas and exclusions.

For example, a network might report a base-case first-year ROI of 28%, a range of 9% to 52%, and a payback period of 14 months. Those results should be connected to inputs: 8,000 annual requests, 600 hours of avoided overtime, 90 recovered requests, $250,000 in implementation and annual operating cost, and $320,000 in verified net benefit. If the dashboard omitted that only 90 requests were recovered—or used gross charges rather than collectible margin—the headline would be misleading.

The report should distinguish realized return from forecast return. At six months, the network may have achieved $110,000 of benefit against $160,000 of cost, producing negative cumulative ROI, while its steady-state forecast remains positive. Presenting both figures is more credible than replacing actual performance with a full-year projection. Management should also note external changes, such as payer portal changes, staffing reorganizations, or new service lines, and recalculate the baseline where those events make comparisons unreliable.

For getpulse.care, the relevant angle is operational visibility across the care network rather than the promise that software can guarantee approvals. A patient-pulse and authorization workflow can make pending status, missing information, denials, appeals, and patient communication visible in one operating model. It still needs payer-specific rules, complete clinical documentation, human exception handling, and financial validation. The best conclusion is therefore conditional: prior authorization ROI is usually positive when avoidable rework, leakage, and staff capacity are large enough to justify a well-run implementation; otherwise, a simpler workflow may be the rational answer.